Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04299373 · ClinicalTrials.gov registry record · Early Phase 1
Surgical Weight Loss and Alcohol Perception
A Early Phase 1 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT04299373: Clinical Trial Early Phase 1 study, sponsored by University of Missouri-Columbia.
NCT04299373 is a Early Phase 1 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04299373, a Early Phase 1 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The study will involve administration of alcohol in a controlled laboratory setting to individuals who are scheduled for Roux-en-Y gastric bypass surgery, and then asking them to return for another laboratory session 3 months following their surgery. A small number will be asked to return again 9 months following their surgery. The primary objective for this research is to collect pilot data on the effects of metabolic surgery (MS), also known as bariatric surgery, on the metabolism of alcohol. These data will be used as preliminary evidence in support of a subsequent application for funding, to be submitted to the National Institutes of Health. A secondary objective for this research is to determine the extent to which MS changes reactivity to alcohol-related cues. Heightened reactivity (e.g., attention bias; craving) to alcohol-related cues is known to signify increased risk for heavy drinking and AUD. No research to date has examined whether the increased sensitivity to alcohol that occurs as a result of MS changes cue-reactivity responses, which in theory reflect an individual's history of learning to associate alcohol consumption with its subjective effects. An exploratory objective is to compare metabolism of alcohol administered orally versus intravenously. IV infusion of alcohol bypasses so-called "first pass metabolism" of alcohol after absorption by the gastrointestinal tract. Thus, compared to oral ingestion, infusion can achieve the same blood alcohol concentration (BAC) with substantially less total alcohol dosage. Following the hypothesis, this should mean that, compared to oral ingestion, infusion will be associated with less production of liver fat, while also mimicking in pre-surgery patients what the investigators observe with oral ingestion following surgery. This comparison will permit better specification of when (during metabolism) and how alcohol is converted to liver fat, and will allow the investigators to separate effects of initial sens
Primary Outcome
Participants' self-reported feelings of stimulation, sedation, and intoxication following exposure to a controlled dose of alcohol in the lab will be assessed using the Subjective Effects of Alcohol Scale (Morean, Corbin, \& Treat, 2013). Possible score values range from 0 to 140, where a score of 0 indicates the absence of any subjective feelings related to consumed alcohol. This scale and its psychometric properties were first described in the following publication: Morean ME, Corbin WR, Trea
Interventions
- DRUG Alcohol: Oral administration
- DRUG Alcohol: Intravenous administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-02-10 |
| Est. Completion | 2022-09-09 |
| Phase | Early Phase 1 |
Why NCT04299373 stopped before completion
NCT04299373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Alcohol: Oral administration is the first listed.
NCT04299373 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04299373 about?
NCT04299373 is a clinical study titled "Surgical Weight Loss and Alcohol Perception". The study will involve administration of alcohol in a controlled laboratory setting to individuals who are scheduled for Roux-en-Y gastric bypass surgery, and then asking them to return for another laboratory session 3 months following their surgery. A small number will be asked to return again 9 mo...
What is the current status of trial NCT04299373?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-02-10. Estimated completion is 2022-09-09.
What interventions are being tested in trial NCT04299373?
The interventions under investigation include: Alcohol: Oral administration (DRUG), Alcohol: Intravenous administration (DRUG).
Who is sponsoring clinical trial NCT04299373?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04299373's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI